Onconova Therapeutics - ONTX Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1 year price targets for Onconova Therapeutics' shares. Their ONTX share price forecasts range from $7.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 978.4% from the stock's current price.
View analysts price targets for ONTX or view top-rated stocks among Wall Street analysts.

Onconova Therapeutics' stock was trading at $2.55 at the beginning of the year. Since then, ONTX shares have decreased by 63.6% and is now trading at $0.9273.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our ONTX earnings forecast.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) issued its quarterly earnings data on Thursday, August, 11th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative net margin of 6,797.79% and a negative trailing twelve-month return on equity of 33.38%.

Shares of Onconova Therapeutics reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Onconova Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.60%), Millennium Management LLC (0.29%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin and Steven M Fruchtman.
View institutional ownership trends.

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ONTX stock can currently be purchased for approximately $0.93.

Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $19.38 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-16,160,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681.